NCT04083963 is a Phase 2 clinical trial of Carboplatin in Triple Negative Breast Cancer, sponsored by University of Illinois at Chicago.

Who is sponsoring NCT04083963?

NCT04083963 is sponsored by University of Illinois at Chicago.

What drugs are being tested in NCT04083963?

Interventions in NCT04083963: Carboplatin, Paclitaxel, Doxorubicin, Cyclophosphamide.

What condition does NCT04083963 study?

NCT04083963 studies Triple Negative Breast Cancer.

Is NCT04083963 still recruiting?

NCT04083963 is currently active, enrolled. Last updated 10 July 2025.

Last reviewed 2025-07-10 · How we verify

NCT04083963

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Active, enrolled Phase 2 Last updated 10 July 2025

What this trial tests

Phase 2 trial testing Carboplatin in Triple Negative Breast Cancer in 13 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 August 2019

Primary endpoint
27 September 2026

27 September 2026

Quick facts

Lead sponsor	University of Illinois at Chicago
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	9 August 2019
Primary completion	27 September 2026
Estimated completion	27 September 2026
Sites	1 location across United States

Drugs / interventions tested

Carboplatin (Carboplatin) — full drug profile →
Paclitaxel — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

University of Illinois at Chicago

Who can join

18 and older, female only, with Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nonrandomized, open label, single arm, Simon's two stage MinMax design trial of neoadjuvant weekly carboplatin plus paclitaxel, followed by doxorubicin and cyclophosphamide in patients with operable Triple Negative Breast Cancer (TNBC)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Early stage triple negative breast cancer: Management and future directions.
Chaudhary LN. · · 2020 · cited 38× · PMID 32507668 · DOI 10.1053/j.seminoncol.2020.05.006
Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review.
Tian H, Ma D, Tan X, Yan W, et al · · 2021 · cited 31× · PMID 34938186 · DOI 10.3389/fphar.2021.770663

Verify or expand the search:

Other trials of Carboplatin

Trials testing the same drug.

NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting

Other recruiting trials for Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting

Other University of Illinois at Chicago trials

Trials by the same sponsor.

NCT07498322 — Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System · NA · not yet recruiting
NCT07387705 — On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial · Phase 1 · not yet recruiting
NCT07504120 — The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis · NA · not yet recruiting
NCT07160582 — Cognitive-Motor Training for AD/ADRD Prevention · NA · not yet recruiting
NCT07498348 — Apple Watch Evaluation of Endodontics Occupational Stress · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04083963 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Illinois at Chicago
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04083963.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing